Literature DB >> 12051711

Only amyloidogenic intermediates of transthyretin induce apoptosis.

Karin Andersson1, Anders Olofsson, Ellen Holm Nielsen, Sven-Erik Svehag, Erik Lundgren.   

Abstract

In diseases like Alzheimer's disease and familial amyloidotic polyneuropathy (FAP) amyloid deposits co-localize with areas of neurodegeneration. FAP is associated with mutations of the plasma protein transthyretin (TTR). We can here show an apoptotic effect of amyloidogenic mutants of TTR on a human neuroblastoma cell line. Toxicity could be blocked by catalase indicating a free oxygen radical dependent mechanism. The toxic effect was dependent on the state of aggregation and unexpectedly mature fibrils from FAP-patients who failed to exert an apoptotic response. Morphological studies revealed a correlation between toxicity and the presence of immature amyloid. Thus, we can show that toxicity is associated with early stages of fibril formation and propose that mature full-length fibrils represent an inert end stage, which might serve as a rescue mechanism. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051711     DOI: 10.1016/S0006-291X(02)00465-5

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy.

Authors:  Ricardo Gomes; Marta Sousa Silva; Alexandre Quintas; Carlos Cordeiro; António Freire; Paulino Pereira; Américo Martins; Estela Monteiro; Eduardo Barroso; Ana Ponces Freire
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

2.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

3.  The effect of membranes on the in vitro fibrillation of an amyloidogenic light-chain variable-domain SMA.

Authors:  Xiaoyun Meng; Anthony L Fink; Vladimir N Uversky
Journal:  J Mol Biol       Date:  2008-06-28       Impact factor: 5.469

4.  Hen lysozyme amyloid fibrils induce aggregation of erythrocytes and lipid vesicles.

Authors:  Nitin Chaudhary; Ramakrishnan Nagaraj
Journal:  Mol Cell Biochem       Date:  2009-03-26       Impact factor: 3.396

5.  Fluctuation methods to study protein aggregation in live cells: concanavalin A oligomers formation.

Authors:  V Vetri; G Ossato; V Militello; M A Digman; M Leone; E Gratton
Journal:  Biophys J       Date:  2011-02-02       Impact factor: 4.033

Review 6.  Prion-like propagation of protein aggregation and related therapeutic strategies.

Authors:  Sarah K Kaufman; Marc I Diamond
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

7.  Prefibrillar aggregates of yeast prion Sup35NM and its variant are toxic to mammalian cells.

Authors:  Yingxia Liu; Haiyan Wei; Jianguo Qu; Jianwei Wang; Tao Hung
Journal:  Neurol Sci       Date:  2011-10-07       Impact factor: 3.307

8.  Human brain astrocytes mediate TRAIL-mediated apoptosis after treatment with IFN-gamma.

Authors:  Jeonggi Lee; Jeon-Soo Shin; In-Hong Choi
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

9.  Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.

Authors:  Dong Hwee Kim; Steven R Zeldenrust; Phillip A Low; Peter J Dyck
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

Review 10.  Use of Noninvasive Imaging in Cardiac Amyloidosis.

Authors:  Raymundo Alain Quintana-Quezada; Syed Wamique Yusuf; Jose Banchs
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.